Innovation in CRC Research: Targeting SPACA6P-AS for Progression
Tianyi Ma1, Yinghu Jin1, Song Wang2
1Department of Colorectal Surgery, the Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Abstract:
The purpose of this research was to provide light on the functional role that the long noncoding RNA SPACA6P-AS plays in the biology of colorectal cancer (CRC). The presence of elevated SPACA6P-AS expression in colorectal cancer tissues is linked to advanced stages of the disease as well as a decreased overall survival rate. It has been demonstrated through knockdown tests conducted on CRC cell lines that SPACA6P-AS stimulates cell growth in both in vitro and in vivo settings. By acting as a competing endogenous RNA, SPACA6P-AS is able to modulate the levels of miR-339-5p and promote the proliferation of colorectal cancer cells by way of the miR-339-5p/FAM167AFAM167A signaling axis. Based on these findings, SPACA6P-AS is a promising candidate for both a prognostic marker and a therapeutic target in colorectal cancer.
Insights
Elevated SPACA6P-AS expression promotes colorectal cancer (CRC) growth and is linked to poor survival. This long noncoding RNA acts as a competing endogenous RNA, targeting miR-339-5p to drive CRC cell proliferation, suggesting it as a therapeutic target.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Colorectal cancer (CRC) remains a significant global health challenge.
- Long noncoding RNAs (lncRNAs) are increasingly recognized for their roles in cancer development.
- The specific function of SPACA6P-AS in CRC pathogenesis requires elucidation.
Purpose of the Study:
- To investigate the functional role of the long noncoding RNA SPACA6P-AS in colorectal cancer (CRC) biology.
- To determine the association between SPACA6P-AS expression levels and CRC progression and patient survival.
- To elucidate the molecular mechanism by which SPACA6P-AS influences CRC cell proliferation.
Main Methods:
- Analysis of SPACA6P-AS expression in colorectal cancer tissues.
- Knockdown experiments in colorectal cancer cell lines (in vitro).
- In vivo studies to assess tumor growth.
- Investigation of the competing endogenous RNA (ceRNA) activity of SPACA6P-AS involving miR-339-5p and the miR-339-5p/FAM167A signaling axis.
Main Results:
- SPACA6P-AS expression is elevated in colorectal cancer tissues and correlates with advanced disease stages and reduced overall survival.
- Knockdown of SPACA6P-AS inhibits colorectal cancer cell proliferation both in vitro and in vivo.
- SPACA6P-AS functions as a competing endogenous RNA, modulating miR-339-5p levels.
- The SPACA6P-AS/miR-339-5p/FAM167A axis promotes colorectal cancer cell proliferation.
Conclusions:
- SPACA6P-AS plays a crucial oncogenic role in colorectal cancer progression.
- SPACA6P-AS is a potential prognostic biomarker for colorectal cancer.
- SPACA6P-AS represents a promising therapeutic target for colorectal cancer treatment.
Related Concept Videos
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...